{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:41:31Z","timestamp":1791499291291,"version":"4.3.4"},"reference-count":142,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T00:00:00Z","timestamp":1667001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Epithelial ovarian cancers (EOC) are often diagnosed at an advanced stage with carcinomatosis and a poor prognosis. First-line treatment is based on a chemotherapy regimen combining a platinum-based drug and a taxane-based drug along with surgery. More than half of the patients will have concern about a recurrence. To improve the outcomes, new therapeutics are needed, and diverse strategies, such as immunotherapy, are currently being tested in EOC. To better understand the global immune contexture in EOC, several studies have been performed to decipher the landscape of tumor-infiltrating lymphocytes (TILs). CD8+ TILs are usually considered effective antitumor immune effectors that immune checkpoint inhibitors can potentially activate to reject tumor cells. To synthesize the knowledge of TILs in EOC, we conducted a review of studies published in MEDLINE or EMBASE in the last 10 years according to the PRISMA guidelines. The description and role of TILs in EOC prognosis are reviewed from the published data. The links between TILs, DNA repair deficiency, and ICs have been studied. Finally, this review describes the role of TILs in future immunotherapy for EOC.<\/jats:p>","DOI":"10.3390\/cancers14215332","type":"journal-article","created":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T23:45:00Z","timestamp":1667087100000},"page":"5332","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Tumor-Infiltrating Lymphocytes (TILs) in Epithelial Ovarian Cancer: Heterogeneity, Prognostic Impact, and Relationship with Immune Checkpoints"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5599-3359","authenticated-orcid":false,"given":"Delphine","family":"Hudry","sequence":"first","affiliation":[{"name":"Inserm, U1192\u2013Prot\u00e9omique R\u00e9ponse Inflammatoire Spectrom\u00e9trie de Masse\u2013PRISM, Lille University, F-59000 Lille, France"},{"name":"Department of Gynecologic Oncology, Oscar Lambret Center, F-59000 Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solenn","family":"Le Guellec","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Oscar Lambret Center, F-59000 Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9386-7978","authenticated-orcid":false,"given":"Samuel","family":"Meignan","sequence":"additional","affiliation":[{"name":"Tumorigenesis and Resistance to Treatment Unit, Centre Oscar Lambret, F-59000 Lille, France"},{"name":"CNRS, Inserm, CHU Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, Lille University, F-59000 Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"B\u00e9court","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Oscar Lambret Center, F-59000 Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Pasquesoone","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Oscar Lambret Center, F-59000 Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7613-8354","authenticated-orcid":false,"given":"Houssein","family":"El Hajj","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Oscar Lambret Center, F-59000 Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Mart\u00ednez-G\u00f3mez","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Oscar Lambret Center, F-59000 Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7299-0339","authenticated-orcid":false,"given":"\u00c9ric","family":"Leblanc","sequence":"additional","affiliation":[{"name":"Inserm, U1192\u2013Prot\u00e9omique R\u00e9ponse Inflammatoire Spectrom\u00e9trie de Masse\u2013PRISM, Lille University, F-59000 Lille, France"},{"name":"Department of Gynecologic Oncology, Oscar Lambret Center, F-59000 Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Narducci","sequence":"additional","affiliation":[{"name":"Inserm, U1192\u2013Prot\u00e9omique R\u00e9ponse Inflammatoire Spectrom\u00e9trie de Masse\u2013PRISM, Lille University, F-59000 Lille, France"},{"name":"Department of Gynecologic Oncology, Oscar Lambret Center, F-59000 Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0331-9194","authenticated-orcid":false,"given":"Sylvain","family":"Ladoire","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Centre Georges-Fran\u00e7ois Leclerc, F-21000 Dijon, France"},{"name":"INSERM, CRI-866 Faculty of Medicine, F-21000 Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(18)32552-2","article-title":"Epithelial ovarian cancer","volume":"393","author":"Lheureux","year":"2019","journal-title":"Lancet"},{"key":"ref_3","unstructured":"World Health Organization (WHO) (2020). Classification of Tumours Editorial Board. Female Genital Tumours, World Health Organization Classification of Tumours."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"896","DOI":"10.6004\/jnccn.2019.0039","article-title":"NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019","volume":"17","author":"Armstrong","year":"2019","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): An open-label, randomised, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1136\/ijgc-2020-001640","article-title":"Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850)","volume":"30","author":"Fagotti","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Kraus, F., El Hajj, H., Le Deley, M.-C., Aissaoui, O., Gachon, B., Chevalier, A., Abdeddaim, C., Lemaire, A.-S., Ben Haj Amor, M., and Sylla, D. (2021). A New Paradigm in Managing Advanced Ovarian Cancer: Differentiating Patients Requiring Neoadjuvant Treatment from Primary Cytoreduction. Cancers, 13.","DOI":"10.3390\/cancers13194925"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.ygyno.2020.05.041","article-title":"A multimodality triage algorithm to improve cytoreductive outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center team ovary initiative","volume":"158","author":"Straubhar","year":"2020","journal-title":"Gynecologic oncology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S1470-2045(20)30218-7","article-title":"Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): Quality-of-life results of a phase 3, randomised, controlled trial","volume":"21","author":"Blagden","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer","volume":"378","author":"Koole","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e2013940","DOI":"10.1001\/jamanetworkopen.2020.13940","article-title":"Evaluation of Cytoreductive Surgery with or without Hyperthermic Intraperitoneal Chemotherapy for Stage III Epithelial Ovarian Cancer","volume":"3","author":"Lei","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1136\/ijgc-2020-001231","article-title":"Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial","volume":"30","author":"Koole","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"100098","DOI":"10.1016\/j.esmoop.2021.100098","article-title":"Rationale and study design of the CHIPPI-1808 trial: A phase III randomized clinical trial evaluating hyperthermic intraperitoneal chemotherapy (HIPEC) for stage III ovarian cancer patients treated with primary or interval cytoreductive surgery","volume":"6","author":"Vanseymortier","year":"2021","journal-title":"ESMO Open"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer","volume":"381","author":"Pautier","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1200\/JCO.20.00799","article-title":"Efficacy of Maintenance Olaparib for Patients with Newly Diagnosed Advanced Ovarian Cancer with a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial","volume":"38","author":"DiSilvestro","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/PAP.0000000000000162","article-title":"Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research","volume":"24","author":"Hendry","year":"2017","journal-title":"Adv. Anat. Pathol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/PAP.0000000000000161","article-title":"Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors","volume":"24","author":"Hendry","year":"2017","journal-title":"Adv. Anat. Pathol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e173290","DOI":"10.1001\/jamaoncol.2017.3290","article-title":"Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer","volume":"3","author":"Goode","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ygyno.2011.09.039","article-title":"Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysis","volume":"124","author":"Hwang","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4887","DOI":"10.1158\/1538-7445.AM2015-4887","article-title":"TCR profiling of T lymphocytes in ovarian tumors and malignant ascites using next-generation sequencing","volume":"75","author":"Jang","year":"2015","journal-title":"Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/s41588-020-0630-5","article-title":"Unraveling tumor\u2013immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy","volume":"52","author":"Cybulska","year":"2020","journal-title":"Nat. Genet."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"eabb0192","DOI":"10.1126\/scitranslmed.abb0192","article-title":"Characterization of ascites- and tumor-infiltrating \u03b3\u03b4 T cells reveals distinct repertoires and a beneficial role in ovarian cancer","volume":"13","author":"Foord","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1177\/1933719112466299","article-title":"Immune response evaluation through determination of type 1, type 2, and type 17 patterns in patients with epithelial ovarian cancer","volume":"20","author":"Silva","year":"2013","journal-title":"Reprod. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"D\u00f6tzer, K., Schl\u00fcter, F., Bo Schoenberg, M., Bazhin, A.V., von Koch, F.E., Schnelzer, A., Anthuber, S., Grab, D., Czogalla, B., and Burges, A. (2019). Immune heterogeneity between primary tumors and corresponding metastatic lesions and response to platinum therapy in primary ovarian cancer. Cancers, 11.","DOI":"10.3390\/cancers11091250"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Tran, E., Nielsen, J.S., Wick, D.A., Ng, A.V., Johnson, L.D.S., Nesslinger, N.J., McMurtrie, E., Webb, J.R., and Nelson, B.H. (2010). Polyfunctional t-cell responses are disrupted by the ovarian cancer ascites environment and only partially restored by clinically relevant cytokines. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0015625"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"357","DOI":"10.4161\/cbt.12.4.16951","article-title":"Tissue-based immune monitoring I: Tumor core needle biopsies allow in-depth interrogation of the tumor microenvironment","volume":"12","author":"Hagemann","year":"2011","journal-title":"Cancer Biol. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"17589","DOI":"10.1038\/s41598-019-53872-1","article-title":"Tumor core biopsies adequately represent immune microenvironment of high-grade serous carcinoma","volume":"9","author":"Lara","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s12253-011-9474-8","article-title":"Weapons ovarian epithelial tumors may use in immune escape: An immunohistochemical correlational study","volume":"18","author":"Hasby","year":"2012","journal-title":"Pathol. Oncol. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1016\/S0140-6736(00)04904-7","article-title":"An overview of the immune system","volume":"357","author":"Parkin","year":"2001","journal-title":"Lancet"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nrc3245","article-title":"The immune contexture in human tumours: Impact on clinical outcome","volume":"12","author":"Fridman","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"5597","DOI":"10.1158\/0008-5472.CAN-16-0431","article-title":"The Emerging Role of B Cells in Tumor Immunity","volume":"76","author":"Tsou","year":"2016","journal-title":"Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"344","DOI":"10.5603\/GP.a2021.0080","article-title":"The relation of CD3, CD4, CD8 and PD-1 expression with tumor type and prognosis in epithelial ovarian cancers","volume":"92","author":"Demiray","year":"2021","journal-title":"Ginekol. Pol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/PGP.0b013e31826a63f8","article-title":"Determination of tumor-infiltrating CD8+ lymphocytes in human ovarian cancer","volume":"32","author":"Aust","year":"2013","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1155\/2020\/8797683","article-title":"Th17 Cells and IL-17 as Novel Immune Targets in Ovarian Cancer Therapy","volume":"2020","author":"Bilska","year":"2020","journal-title":"J. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3892\/ol.2016.5428","article-title":"Differential distribution of tumor-associated macrophages and Treg\/Th17 cells in the progression of malignant and benign epithelial ovarian tumors","volume":"13","author":"Zhu","year":"2017","journal-title":"Oncol. Lett."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ygyno.2010.05.016","article-title":"Profound elevation of CD8+ T cells expressing the intraepithelial lymphocyte marker CD103 (\u03b1E\/\u03b27 Integrin) in high-grade serous ovarian cancer","volume":"118","author":"Webb","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1002\/JLB.5MA1119-265R","article-title":"Bispecific antibodies enhance tumor-infiltrating T cell cytotoxicity against autologous HER-2-expressing high-grade ovarian tumors","volume":"107","author":"Oberg","year":"2020","journal-title":"J. Leukoc. Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"214ra169","DOI":"10.1126\/scitranslmed.3007247","article-title":"Digital genomic quantification of tumor-infiltrating lymphocytes","volume":"5","author":"Robins","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_45","first-page":"1","article-title":"Intraepithelial T cells and tumor-associated macrophages in ovarian cancer patients","volume":"13","author":"Wang","year":"2013","journal-title":"Cancer Immun."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/s41416-019-0384-y","article-title":"Tumour-reactive T cell subsets in the microenvironment of ovarian cancer","volume":"120","author":"Westergaard","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00262-014-1636-6","article-title":"Activated regulatory and memory T-cells accumulate in malignant ascites from ovarian carcinoma patients","volume":"64","author":"Landskron","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40425-014-0038-9","article-title":"Detailed characterization of tumor infiltrating lymphocytes in two distinct human solid malignancies show phenotypic similarities","volume":"2","author":"Chisholm","year":"2014","journal-title":"J. ImmunoTherapy Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.ygyno.2009.11.020","article-title":"Ovarian cancer tumor infiltrating T-regulatory (Treg) cells are associated with a metastatic phenotype","volume":"116","author":"Barnett","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1158\/1078-0432.CCR-15-2762","article-title":"Tumor-infiltrating plasma cells are associated with tertiary lymphoid structures, cytolytic T-cell responses, and superior prognosis in ovarian cancer","volume":"22","author":"Kroeger","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network (2011). Integrated genomic analyses of ovarian carcinoma. Nature, 474, 609\u2013615.","DOI":"10.1038\/nature10166"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1038\/ncomms3612","article-title":"Inferring tumour purity and stromal and immune cell admixture from expression data","volume":"4","author":"Yoshihara","year":"2013","journal-title":"Nat. Commun."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat. Methods"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"346","DOI":"10.31083\/j.ejgo.2021.02.5347","article-title":"Profiles of immune infiltration in ovarian cancer and their clinical significance: A gene expression-based study","volume":"42","author":"Zhou","year":"2021","journal-title":"Eur. J. Gynaecol. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1760067","DOI":"10.1080\/2162402X.2020.1760067","article-title":"Heterogeneity of immune microenvironment in ovarian cancer and its clinical significance: A retrospective study","volume":"9","author":"Gao","year":"2020","journal-title":"OncoImmunology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1039\/C8MO00128F","article-title":"Clinical significance of the immune microenvironment in ovarian cancer patients","volume":"14","author":"Yang","year":"2018","journal-title":"Mol. Omics"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.ajpath.2015.12.029","article-title":"Establishment of a Novel Histopathological Classification of High-Grade Serous Ovarian Carcinoma Correlated with Prognostically Distinct Gene Expression Subtypes","volume":"186","author":"Murakami","year":"2016","journal-title":"Am. J. Pathol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"529","DOI":"10.21873\/cgp.20209","article-title":"Multisite Tumor Sampling Reveals Extensive Heterogeneity of Tumor and Host Immune Response in Ovarian Cancer","volume":"17","author":"Lakis","year":"2020","journal-title":"Cancer Genom. Proteom."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"7621","DOI":"10.1158\/1078-0432.CCR-17-1159","article-title":"A complex network of tumor microenvironment in human high-grade serous ovarian cancer","volume":"23","author":"Kreuzinger","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.humpath.2017.12.010","article-title":"Tumor-associated macrophages and the tumor immune microenvironment of primary and recurrent epithelial ovarian cancer","volume":"74","author":"Ojalvo","year":"2018","journal-title":"Hum. Pathol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"109165","DOI":"10.1016\/j.celrep.2021.109165","article-title":"Characterizing the tumor microenvironment of metastatic ovarian cancer by single-cell transcriptomics","volume":"35","author":"Olalekan","year":"2021","journal-title":"Cell Rep."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Zhu, Y., Ferri-Borgogno, S., Sheng, J., Yeung, T.L., Burks, J.K., Cappello, P., Jazaeri, A.A., Kim, J.H., Han, G.H., and Birrer, M.J. (2021). Sio: A spatioimageomics pipeline to identify prognostic biomarkers associated with the ovarian tumor microenvironment. Cancers, 13.","DOI":"10.3390\/cancers13081777"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"367","DOI":"10.4161\/cbt.12.4.16908","article-title":"Tissue-based immune monitoring II: Multiple tumor sites reveal immunologic homogeneity in serous ovarian carcinoma","volume":"12","author":"Hagemann","year":"2011","journal-title":"Cancer Biol. Ther."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1158\/1538-7445.AM2017-3991","article-title":"Profiling the immune tumor microenvironment in primary and recurrent epithelial ovarian cancer","volume":"77","author":"Ojalvo","year":"2017","journal-title":"Cancer Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e1593811","DOI":"10.1080\/2162402X.2019.1593811","article-title":"Immune mediator expression signatures are associated with improved outcome in ovarian carcinoma","volume":"8","author":"Nakamura","year":"2019","journal-title":"OncoImmunology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"James, F.R., Jiminez-Linan, M., Alsop, J., Mack, M., Song, H., Brenton, J.D., Pharoah, P.D.P., and Ali, H.R. (2017). Association between tumour infiltrating lymphocytes, histotype and clinical outcome in epithelial ovarian cancer. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3585-x"},{"key":"ref_68","first-page":"4557","article-title":"Stromal tumor-infiltrating lymphocytes evaluated on H&E-stained slides are an independent prognostic factor in epithelial ovarian cancer and ovarian serous carcinoma","volume":"17","author":"Hwang","year":"2019","journal-title":"Oncol. Lett."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/apm.13116","article-title":"Immunotyping in tubo-ovarian high-grade serous carcinoma by PD-L1 and CD8+ T-lymphocytes predicts disease-free survival","volume":"129","author":"Bansal","year":"2021","journal-title":"APMIS"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"18538","DOI":"10.1073\/pnas.0509182102","article-title":"Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+\/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer","volume":"102","author":"Sato","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0611533104","article-title":"Programmed Cell Death 1 Ligand 1 and Tumor-Infiltrating CD8\u207a T Lymphocytes Are Prognostic Factors of Human Ovarian Cancer","volume":"104","author":"Hamanishi","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2009-03-208249","article-title":"Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments","volume":"114","author":"Kryczek","year":"2009","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nm1093","article-title":"Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival","volume":"10","author":"Curiel","year":"2004","journal-title":"Nat. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00262-008-0583-5","article-title":"Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer","volume":"58","author":"Leffers","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Milne, K., K\u00f6bel, M., Kalloger, S.E., Barnes, R.O., Gao, D., Gilks, C.B., Watson, P.H., and Nelson, B.H. (2009). Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0006412"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.18632\/oncotarget.27666","article-title":"Clonality and antigen-specific responses shape the prognostic effects of tumor-infiltrating T cells in ovarian cancer","volume":"11","author":"Tsuji","year":"2020","journal-title":"Oncotarget"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1002\/cam4.3942","article-title":"Spatial cytotoxic and memory T cells in tumor predict superior survival outcomes in patients with high-grade serous ovarian cancer","volume":"10","author":"Zhang","year":"2021","journal-title":"Cancer Med."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Han, G.H., Hwang, I., Cho, H., Ylaya, K., Choi, J.A., Kwon, H., Chung, J.Y., Hewitt, S.M., and Kim, J.H. (2021). Clinical Significance of Tumor Infiltrating Lymphocytes in Association with Hormone Receptor Expression Patterns in Epithelial Ovarian Cancer. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22115714"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1158\/1541-7786.MCR-19-0449","article-title":"Serum CD95L level correlates with tumor immune infiltration and is a positive prognostic marker for advanced high-grade serous ovarian cancer","volume":"17","author":"Cauchois","year":"2019","journal-title":"Mol. Cancer Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4049\/jimmunol.188.Supp.74.9","article-title":"CD4+CD25+FOXP3+ regulatory T cells and association with survival in epithelial ovarian cancer","volume":"188","author":"Preston","year":"2012","journal-title":"J. Immunol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ygyno.2016.07.105","article-title":"Systematic evaluation of multiple immune markers reveals prognostic factors in ovarian cancer","volume":"143","author":"Santoiemma","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"ref_82","first-page":"55","article-title":"Do tumor-infiltrating lymphocytes really indicate favorable prognosis in epithelial ovarian cancer?","volume":"215","author":"Yildirim","year":"2017","journal-title":"EJOG"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ygyno.2019.04.153","article-title":"Lymphocyte-specific protein tyrosine kinase expression predicts survival in ovarian high-grade serous carcinoma","volume":"154","author":"Hinchcliff","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00428-020-02751-6","article-title":"PD-1\/PD-L1 expression and tumor-infiltrating lymphocytes are prognostically favorable in advanced high-grade serous ovarian carcinoma","volume":"477","author":"Arildsen","year":"2020","journal-title":"Virchows Arch."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.neo.2018.01.007","article-title":"Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer","volume":"20","author":"Stanske","year":"2018","journal-title":"Neoplasia"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"119461","DOI":"10.1016\/j.lfs.2021.119461","article-title":"Prognostic value of immune-related cells and genes in the tumor microenvironment of ovarian cancer, especially CST4","volume":"277","author":"Wang","year":"2021","journal-title":"Life Sci."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2018.07.025","article-title":"Patient inflammatory status and CD4+\/CD8+ intraepithelial tumor lymphocyte infiltration are predictors of outcomes in high-grade serous ovarian cancer","volume":"151","author":"Pinto","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1007\/s00262-019-02385-x","article-title":"Lymphocyte-specific kinase expression is a prognostic indicator in ovarian cancer and correlates with a prominent B cell transcriptional signature","volume":"68","author":"Hinchcliff","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1158\/1078-0432.CCR-12-0234","article-title":"CD20+ tumor-infiltrating lymphocytes have an atypical CD27\u2014Memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer","volume":"18","author":"Nielsen","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Hermans, C., Anz, D., Engel, J., Kirchner, T., Endres, S., and Mayr, D. (2014). Analysis of FoxP3+ T-regulatory cells and CD8+T-Cells in ovarian carcinoma: Location and tumor infiltration patterns are key prognostic markers. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0111757"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1158\/2326-6066.CIR-14-0146","article-title":"CD25 identifies a subset of CD4 FoxP3 TIL that are exhausted yet prognostically favorable in Human Ovarian cancer","volume":"3","author":"Kroeger","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s43046-021-00073-5","article-title":"Programmed death ligand-1 and CD8 tumor-infiltrating lymphocytes (TILs) as prognostic predictors in ovarian high-grade serous carcinoma (HGSC)","volume":"33","author":"Farrag","year":"2021","journal-title":"J. Egypt. Natl. Cancer Inst."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Bachmayr-Heyda, A., Aust, S., Heinze, G., Polterauer, S., Grimm, C., Braicu, E.I., Sehouli, J., Lambrechts, S., Vergote, I., and Mahner, S. (2013). Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients\u2014A study of the OVCAD consortium. BMC Cancer, 13.","DOI":"10.1186\/1471-2407-13-422"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Preston, C.C., Maurer, M.J., Oberg, A.L., Visscher, D.W., Kalli, K.R., Hartmann, L.C., Goode, E.L., and Knutson, K.L. (2013). The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0080063"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1158\/1078-0432.CCR-20-4394","article-title":"Single-cell profiles and prognostic impact of tumor-infiltrating lymphocytes coexpressing CD39, CD103, and PD-1 in ovarian cancer","volume":"27","author":"Laumont","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1158\/1078-0432.CCR-13-1877","article-title":"Tumor-infiltrating lymphocytes expressing the tissue resident memory marker cd103 are associated with increased survival in high-grade serous ovarian cancer","volume":"20","author":"Webb","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1935104","DOI":"10.1080\/2162402X.2021.1935104","article-title":"Prognostic image-based quantification of CD8CD103 T cell subsets in high-grade serous ovarian cancer patients","volume":"10","author":"Paijens","year":"2021","journal-title":"Oncoimmunology"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Khalique, S., Nash, S., Mansfield, D., Wampfler, J., Attygale, A., Vroobel, K., Kemp, H., Buus, R., Cottom, H., and Roxanis, I. (2021). Quantitative Assessment and Prognostic Associations of the Immune Landscape in Ovarian Clear Cell Carcinoma. Cancers, 13.","DOI":"10.3390\/cancers13153854"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1158\/1078-0432.CCR-13-3368","article-title":"Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer","volume":"20","author":"Iglesia","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13048-016-0232-0","article-title":"Prognostic impact of tumour-associated B cells and plasma cells in epithelial ovarian cancer","volume":"9","author":"Lundgren","year":"2016","journal-title":"J. Ovarian Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e27668","DOI":"10.4161\/onci.27668","article-title":"Location, location, location: CD103 demarcates intraepithelial, prognostically favorable CD8+ tumor-infiltrating lymphocytes in ovarian cancer","volume":"3","author":"Webb","year":"2014","journal-title":"Oncoimmunology"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/cei.13639","article-title":"Prognostic implications of tumour-infiltrating lymphocytes for recurrence in epithelial ovarian cancer","volume":"206","author":"Wu","year":"2021","journal-title":"Clin. Exp. Immunol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"616073","DOI":"10.3389\/fgene.2021.616073","article-title":"Comprehensive Analysis of Tumor Microenvironment Identified Prognostic Immune-Related Gene Signature in Ovarian Cancer","volume":"12","author":"Li","year":"2021","journal-title":"Front. Genet."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1097\/PAS.0000000000001503","article-title":"PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Different Types of Tubo-ovarian Carcinoma and Their Prognostic Value in High-grade Serous Carcinoma","volume":"44","author":"Chen","year":"2020","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ygyno.2018.02.009","article-title":"Mismatch repair deficiency is associated with MSI phenotype, increased tumor-infiltrating lymphocytes and PD-L1 expression in immune cells in ovarian cancer","volume":"149","author":"Xiao","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Testa, U., Petrucci, E., Pasquini, L., Castelli, G., and Pelosi, E. (2018). Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells. Medicines, 5.","DOI":"10.3390\/medicines5010016"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.omtn.2020.12.005","article-title":"lncRNA-Xist\/miR-101-3p\/KLF6\/C\/EBP\u03b1 axis promotes TAM polarization to regulate cancer cell proliferation and migration","volume":"23","author":"Zhao","year":"2021","journal-title":"Mol. Ther.\u2014Nucleic Acids"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"e000375","DOI":"10.1136\/jitc-2019-000375","article-title":"Neoantigen load and HLA-class i expression identify a subgroup of tumors with a T-cell-inflamed phenotype and favorable prognosis in homologous recombination-proficient high-grade serous ovarian carcinoma","volume":"8","author":"Matsushita","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"13587","DOI":"10.18632\/oncotarget.7277","article-title":"Association and prognostic significance of BRCA1\/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1\/PD-L1 in high grade serous ovarian cancer","volume":"7","author":"Strickland","year":"2016","journal-title":"Oncotarget"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"e10255","DOI":"10.7717\/peerj.10255","article-title":"Comprehensive genomic analysis of microenvironment phenotypes in ovarian cancer","volume":"8","author":"Wang","year":"2020","journal-title":"PeerJ"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ygyno.2019.02.011","article-title":"Tumor infiltrating lymphocytes and homologous recombination deficiency are independently associated with improved survival in ovarian carcinoma","volume":"153","author":"Morse","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e10414","DOI":"10.7717\/peerj.10414","article-title":"Classification of ovarian cancer associated with BRCA1 mutations, immune checkpoints, and tumor microenvironment based on immunogenomic profiling","volume":"8","author":"Wei","year":"2020","journal-title":"PeerJ"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.ygyno.2021.07.001","article-title":"Lynch syndrome-associated epithelial ovarian cancer and its immunological profile","volume":"162","author":"Rasmussen","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/PGP.0000000000000657","article-title":"Expression of the Immune Checkpoints LAG-3 and PD-L1 in High-grade Serous Ovarian Carcinoma: Relationship to Tumor-associated Lymphocytes and Germline BRCA Status","volume":"39","author":"Whitehair","year":"2020","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1038\/s41467-018-06130-3","article-title":"Microenvironmental niche divergence shapes BRCA1-dysregulated ovarian cancer morphological plasticity","volume":"9","author":"Heindl","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"i11","DOI":"10.1093\/annonc\/mdw084","article-title":"Opportunities in immunotherapy of ovarian cancer","volume":"27","author":"Coukos","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"e1786","DOI":"10.1002\/onco.13887","article-title":"Systematic Review of PD-1\/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health","volume":"26","author":"Chang","year":"2021","journal-title":"Oncologist"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s40425-019-0768-9","article-title":"The role of PD-L1 expression as a predictive biomarker: An analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors","volume":"7","author":"Davis","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1158\/2326-6066.CIR-14-0239","article-title":"PD-1 and CD103 are widely coexpressed on prognostically favorable intraepithelial CD8 T cells in human ovarian cancer","volume":"3","author":"Webb","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ygyno.2016.03.008","article-title":"PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer","volume":"141","author":"Webb","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.18632\/oncotarget.6429","article-title":"Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumorinfiltrating lymphocytes in ovarian high grade serous carcinoma","volume":"7","author":"Kunze","year":"2016","journal-title":"Oncotarget"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.1158\/1078-0432.CCR-18-4175","article-title":"TIM-3 dictates functional orientation of the immune infiltrate in ovarian cancer","volume":"25","author":"Fucikova","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.intimp.2017.08.017","article-title":"Prognostic value of tumor PD-L1 expression combined with CD8(+) tumor infiltrating lymphocytes in high grade serous ovarian cancer","volume":"52","author":"Wang","year":"2017","journal-title":"Int. Immunopharmacol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13048-019-0526-0","article-title":"PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma","volume":"12","author":"Kim","year":"2019","journal-title":"J. Ovarian Res."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/intimm\/dxaa010","article-title":"PD-1+Tim3+tumor-infiltrating CD8 T cells sustain the potential for IFN-\u03b3production, but lose cytotoxic activity in ovarian cancer","volume":"32","author":"Sawada","year":"2020","journal-title":"Int. Immunol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"6400","DOI":"10.1038\/s41598-021-85966-0","article-title":"PD-1 and PD-L1 expression on TILs in peritoneal metastases compared to ovarian tumor tissues and its associations with clinical outcome","volume":"11","author":"Bekos","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41577-019-0224-6","article-title":"TIM3 comes of age as an inhibitory receptor","volume":"20","author":"Wolf","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1007\/s00262-019-02402-z","article-title":"Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy","volume":"68","author":"Forget","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1158\/1078-0432.CCR-15-2657","article-title":"Neoadjuvant chemotherapy modulates the immune microenvironment in metastases of tubo-ovarian high-grade serous carcinoma","volume":"22","author":"Montfort","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00428-020-02795-8","article-title":"The effect of the peritoneal tumor microenvironment on invasion of peritoneal metastases of high-grade serous ovarian cancer and the impact of NEOADJUVANT chemotherapy","volume":"477","author":"Lok","year":"2020","journal-title":"Virchows Arch."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s00262-010-0817-1","article-title":"Foxp3+ cell infiltration and granzyme B+\/Foxp3 + cell ratio are associated with outcome in neoadjuvant chemotherapy-treated ovarian carcinoma","volume":"59","author":"Braun","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/ijgc-2018-000092","article-title":"Histopathologic response to neoadjuvant chemotherapy as a prognostic biomarker in tubo-ovarian high-grade serous carcinoma: Updated Chemotherapy Response Score (CRS) results","volume":"29","author":"Le","year":"2019","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/annonc\/mdw625","article-title":"Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC)","volume":"28","author":"Mesnage","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrc1613","article-title":"Immunotherapy and chemotherapy\u2014A practical partnership","volume":"5","author":"Lake","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/eji.200324181","article-title":"CD4\u207aCD25\u207a regulatory T\u2004cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative","volume":"34","author":"Ghiringhelli","year":"2004","journal-title":"Eur. J. Immunol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00262-020-02670-0","article-title":"Neoadjuvant chemotherapy alters the balance of effector to suppressor immune cells in advanced ovarian cancer","volume":"70","author":"Leary","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1038\/s41467-018-03301-0","article-title":"Sensitive and frequent identification of high avidity neo-epitope specific CD8+ T cells in immunotherapy-naive ovarian cancer","volume":"9","author":"Bobisse","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_139","first-page":"1","article-title":"Immune Therapy Opportunities in Ovarian Cancer","volume":"40","author":"Kandalaft","year":"2020","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"17588359211008399","DOI":"10.1177\/17588359211008399","article-title":"Cell therapies in ovarian cancer","volume":"13","author":"Sarivalasis","year":"2021","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Aust, S., Schwameis, R., Gagic, T., M\u00fcllauer, L., Langthaler, E., Prager, G., Grech, C., Reinthaller, A., Krainer, M., and Pils, D. (2020). Precision Medicine Tumor Boards: Clinical Applicability of Personalized Treatment Concepts in Ovarian Cancer. Cancers, 12.","DOI":"10.3390\/cancers12030548"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"e417","DOI":"10.1016\/S1470-2045(19)30401-2","article-title":"Rational combinations of immunotherapy with radiotherapy in ovarian cancer","volume":"20","author":"Herrera","year":"2019","journal-title":"Lancet Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/21\/5332\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:05:39Z","timestamp":1760144739000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/21\/5332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,29]]},"references-count":142,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["cancers14215332"],"URL":"https:\/\/doi.org\/10.3390\/cancers14215332","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,29]]}}}